Palladium-Catalyzed Dehalogenation of 5-Halopyrazoles

Chun-Yen Chen, Yu-Ying Huang, Wei-Nien Su, Kimiyoshi Kaneko, Masayuki Kimura, Hiroyuki Takayama, and Fung Fuh Wong *

^aDepartment of Chemistry, National Cheng Kung University, No. 1, Ta Hsueh Rd., Tainan, Taiwan 70101, Republic of China

^bGraduate Institute of Pharmaceutical Chemistry, China Medical University, No. 91, Hsueh-Shih Rd., Taichung, Taiwan 40402, Republic of China

^cDepartment of Medico Pharmaceutical Science, Nihon Pharmaceutical University, 10281, Komuro, Inamachi, Kita-Adachigun, Saitama, Japan

*E-mail: wongfungfuh@yahoo.com.tw (or) ffwong@mail.cmu.edu.tw Received September 29, 2010 DOI 10.1002/jhet.845

Published online 27 October 2011 in Wiley Online Library (wileyonlinelibrary.com).

$$W-N$$
 R
 $X = CI \text{ or Br}$
 $H_2, PdCl_2(PPh_3)_2$
 $tBuOK, toluene$
 $W = Aryl, Phenyl$
 $R = n-Pr, i-Pr, Ph$

A new and efficient method for the dehalogenation of 5-halopyrazoles was developed by using the catalytic amount of palladium (II) chloride and triphenylphosphine as a ligand at reflux under constant flow of hydrogen gas. The reaction gave the corresponding pyrazole products in good to excellent yields (>83%).

J. Heterocyclic Chem., 49, 183 (2012).

INTRODUCTION

Pyrazoles [1] and pyrazolones [2] are an important family of heterocyclic compounds because of their wide range of pharmacological properties [3–11]. In particular, modified pyrazoles [12–18], pyrazolones [19–21], and polypyrroles [22–27] are the component of various active materials. They are also key starting materials for the synthesis of commercial aryl/hetarylpyrazolone dye [28–30] and acting as the efficient ligand [31] for the construction of various organometallic catalysts especially with early transition metals and lanthanides.

A halogen atom is often introduced to a given position of an arene or a heterocyclic compound to make them as the blocking group [32–36]. Occasionally, it is introduced from the side reactions [37]. A great number of halogenated organic compounds are hazardous pollutants widely distributed in the environment, especially polychlorinated biphenyls [38–41]. However, the dehalogenation is an important chemical transformation in organic synthesis and environmental remediation [42–45].

Many dehalogenation methods have been developed over years [46]. Recently, several new methods were provided by employing palladium [39,47–56], rhodium [53], iron [54], and nickel [55,56] as the catalysts. In particular, palladium catalyst is a very stable, readily commercially available, inexpensive, and comparatively nonhazardous source of hydrogen donor. However, a large number of methodologies are developed and used

toward aryl halides, especially aryl chlorides [47–59]. To the best of our knowledge, a few dehalogenation methods were performed in the heterocyclic or pyrazole systems according to the stronger bond energy of carbon–halogen [60–62]. Whatever, the withdrawing groups (e.g., carbonyl group) was introduced toward the heterocyclic or pyrazole systems to promote the dehalogenation [61]. In this article, we report the first use of palladium chloride in the presence of triphenylphosphine and potassium *tert*-butoxide to remove the halogen atom in pyrazoles.

RESULTS AND DISCUSSION

As shown in Scheme 1, 5-halopyrazoles 3–13 were served as the substrates for the study of the newly developed dehalogenation method. Pyrazolones 1 and 5-hydroxypyrazoles 2, served as the starting material, were obtained by reacting α-keto esters with equal equivalent of arylhydrazines through tandem condensation and thermal cyclization reaction [21,63]. 5-Bromopyrazoles 3–10 were prepared from 1 with PBr₃ in refluxing acetonitrile [63], and 5-bromopyrazoles 11–12 with 5-chloropyrazole 13 were prepared from the reaction of 2 with pure POCl₃ or POBr₃ at 60°C [64,65].

To search for the best palladium catalyst and phosphine ligand, we chose 1,3-diphenyl-5-bromopyrazole 5 as the model for the dehalogenation reaction (Scheme 2

Scheme 1

and Table 1). When compound 5 was reacted with various palladium catalysts including palladium chloride (PdCl₂), palladium acetylacetonate (Pd(OAc)₂), and Pd(PPh₃)₄, the poor yields of the product were obtained (<46%, see entry 1 and 4 of Table 1). Using PdCl₂ or Pd(OAc)₂ as the catalyst in presence of various of bulky phosphine ligands including 1,4-bis(diphenylphosphino)-1,1-bis(diphenylphosphino)ferrocene butane, triphenylphosphine (PPh₃), tri-o-tolylphosphine (P(o $tolyl)_3),$ and tri-2,4,6-tri-methoxyphenylphosphine P(2,4,6-tri-OMePh)₃ provided the model product **16** in good to excellent yields (≥93%, see entry 2–7 of Table 1). Considering the reactivity and the law material cost, we envisioned that the commercially available palladium chloride and triphenylphosphine PPh3 were the best dehalogenated catalyst and ligand for this reaction.

To investigate the effect of alkali-metal base, we applied the standard procedure to 1,3-diphenyl-5-bromopyrazole 5 in presence of palladium chloride and triphenylphosphine with 2.0 equivalents of the different bases including cesium and potassium carbonate, sodium hydrogencarbonate, and sodium methoxide. However, only the poor result was obtained and most of starting material was recovered (see entry 9–12 of Table 1). When pyridine was used as a base under the same con-

dition for 1,3-diphenyl-5-bromopyrazole **5**, we did not detect the dehalogenated product **16** (see entry 13 of Table 1). The study showed the reactivity of bases was $t\text{-BuOK} > \text{K}_2\text{CO}_3 > \text{CsCO}_3 > \text{NaHCO}_3 > \text{NaOMe} > \text{pyridine for the reaction.}$

In the newly developed dehalogenation method, we first generated PdCl₂(PPh₃)₂ by reacting PdCl₂ with triphenylphosphine (PPh₃) in EtOH at 60°C [66,67]. 5-Halopyrazoles **3–13** were then treated with catalyst amount (3.0 mol %) of the resulting catalyst in toluene at reflux for 1–4 h under hydrogen atmosphere. The reaction provided the corresponding dehalogenated products **14–23** in good to excellent yields (Table 2). For simple 5-bromo-1-phenylpyrazoles **3–5** bearing *n*-propyl, *i*-propyl, or phenyl group at the C-3 position of the pyrazole ring, the desired dehalogenation products **14–16** were obtained in good to excellent yields (92–98%, Table 2).

To search for the effect of the substitution on the pyrazole ring, the newly dehalogenation method was applied to substrates **6–12**, which were attached with *o*-Me-Ph, *p*-OMe-Ph, *p*-Cl-Ph, *p*-Br-Ph, 2,4,6-tri-Cl-Ph, 2-quinolinyl, or pyridyl groups at the *N*-1 position of the pyrazole. For compound **6** and **7** with *o*-Me-Ph and *p*-OMe-Ph, the reaction provided the corresponding debromination products **17–18** in 92–95% yields (Table 2). The bromo atom on the pyrazole ring of compounds **8** and **9** with *p*-Cl-Ph or *p*-Br-Ph at the C-5 position was also debrominated. However, the debromination also

Table 1

The optimization study of dehalogenation of 5-bromopyrazole 5.

Entry Catalyst ^a		Ligand	Base	Yields of product 16 (%)	
1	PdCl ₂	_	t-BuOK	4	
2	$PdCl_2$	PPh_3	t-BuOK	98	
3	PdCl ₂	dppf	t-BuOK	96	
4	$Pd(OAc)_2$	-	t-BuOK	46	
5	$Pd(OAc)_2$	P(tolyl) ₃	t-BuOK	97	
6	$Pd(OAc)_2$	$P(2,4,6-tri-OMePh)_3$	t-BuOK	93	
7	$Pd(OAc)_2$	1,4-bis(diphenylphosphino)butane	t-BuOK	95	
8	$Pd(PPh)_4$	PPh ₃	t-BuOK	51	
9	$PdCl_2$	PPh_3	K_2CO_3	76	
10	$PdCl_2$	PPh_3	CsCO ₃	54	
11	PdCl ₂	PPh ₃	NaOMe	Not detectable	
12	PdCl ₂	PPh_3	NaHCO ₃	Trace	
13	$PdCl_2$	PPh ₃	Pyridine	Not detectable	

^a The amount of catalysts was used 0.03 equivalent

 $\label{eq:Table 2} Table \ 2$ The results of dehalogenation of 5-halopyrazoles 3–13 by using PdCl2(PPh3)2 as the catalyst.

5-Halopyrazoles (3–13)				Pyrazoles (14–23)			
S.M.	X	W	R	Products	X	Yields (%)	
3	Br	Ph	n-Pr	14	Н	94 ^b	
4	Br	Ph	<i>i</i> -Pr	15	Н	92	
5	Br	Ph	Ph	16	Н	98 ^b	
6	Br	o-Me-Ph	Ph	17	Н	95	
7	Br	p-OMe-Ph	Ph	18	Н	92 ^b	
8	Br	p-Cl-Ph	Ph	19	Н	83 ^b	
9	Br	p-Br-Ph	Ph	16 (W = Ph)	Н	96	
10	Br	2,4,6-tri-Cl-Ph	Ph	20 (W = 2.6 -di-Cl-Ph)	Н	52	
				21 (W = $2,4,6$ -tri-Cl-Ph)	Н	44 ^b	
11	Br	2-quinolinyl	Ph	22	Н	85	
12	Br	Pyridyl	Ph	23	Н	88	
13	Cl	Pyridyl	Ph	23	Н	84	

^a Catalyst PdCl₂(PPh₃)₂ was prepared by following the previous reported procedure [66,67].

took place on the phenyl ring in compound 9 to give the corresponding didebrominated product 16 in 96% yield (Table 2). As a result, the reaction was applicable to the aromatic and pyrazolic halide compounds. When we extended the same condition to 5-bromo-1-(2,4,6-tri-chlorophenyl)pyrazole 10, the corresponding debromination product 20 and didehalogenation product 21 were obtained in 52% and 44% yields, respectively (Table 2).

The dehalogenation also proceeded smoothly in compounds 11–13 bearing N-1 2-quinolinyl or pyridyl group. The expected corresponding products 22 and 23 were obtained 85 and 88% yields, respectively (Table 2). Comparing the reaction conditions for 12 and 13, we found that the dechlorination is more difficult than debromination (Table 2). For example, the reaction time for the dechlorination reaction for 13 should be prolonged to 8 h to provide the 23 in good yield [71]. The structure of dehalogenated products 14-23 were fully characterized by spectroscopic methods. Served as an example, compound 16 possessed pyrazole ring characteristic peaks: a doublet resonance at δ 6.78 ppm for the C-4 proton, a doublet resonance at δ 7.96 ppm for the C-5 proton, and at δ 105.02 and 126.32 ppm, which represented the ¹³C in tertiary carbon in C-4 and C-5 on the pyrazole ring.

A general catalytic cycle for dehalogenation of 5-halopyrazoles **24** to pyrazoles **28** in the presence of palladium, phosphine, and *t*-BuOK base was depicted in Scheme 3 [72]. In the first step of this catalytic cycle, it involves the oxidation–addition process for the formation of the active catalyst Pd(0)L₂ to active the pyrazole–halogen bond **25** by coordination of PPh₃ ligand. The second step is *t*-BuOK base attacking the palladium atom and replacing halide to form the pyrazole–palladium complex **26** and potassium halide [73]. In the next step, palladium

complex **26** was rapidly converted to generate palladium hydride complex **27** with bubble H_2 . Consequently, the reduction–elimination step was followed to give the dehalogenated pyrazole product **28** and regenerate the Pd (0) species under hydrogen atmosphere.

In conclusion, we have successfully developed a new palladium-catalyzed dehalogenation reaction for 5-halopyrazoles by using palladium chloride as a catalyst and triphenylphosphine as a ligand at reflux with bubble H₂. The reaction gave the corresponding dehalogenated products in excellent yields.

EXPERIMENTAL

General procedure. Pyrazolones 1 or 5-hydroxypyrazoles 2 were synthesized according to literature

^b Compounds 14, 16, 18–19, and 21 were reported previously, our spectroscopic data (14 [68], 16 [69], 18–19, and 21 [70]) are consistent with those of an authentic sample or published data in the literature.

procedure [21,63]. All chemicals were reagent grade and used as purchased unless otherwise noted. All reactions were monitored by TLC. Flash column chromatography was carried out on silica gel (70-230 mesh). Dichloromethane, ethyl acetate, hexanes, and toluene were purchased from Mallinckrodt Chemical. The following compounds were purchased from Acros Chemical: o-tolyhydrazine hydrochorolide, *n*-propyl acetoacetate, 4-bromophenylhydrazine hydrochloride, 4-chlorophenylhydrazine hydrochloride, ethyl isopropylacetate, 4-methoxyphenylhydrazine hydrochloride, palladium acetylacetonate, palladium chloride, phenylhydrazine, and tetrakis(triphenylphosphine)palladium. 2,4,6-Trichlorophenyl hydrazine, 2-hydrazinopyridine, and isonicotinic acid hydrazide, 1,1-bis(diphenylphosphino)ferrocene were purchased from TCI Chemical. 1,4-Bis(diphenylphosphino)butane, ethyl benzoylacetate, triphenylphosphine, tri-otolylphosphine, tri-2,4,6-tri-methoxyphenylphosphine were purchased from Alfa Chemical. Purification by gravity column chromatography was carried out by use of Merck Reagents Silica Gel 60 (particle size 0.063– 0.200 mm, 70-230 mesh ASTM). Infrared (IR) spectra were measured on a Bomem Michelson Series FT-IR spectrometer. The wavenumbers reported are referenced to the polystyrene 1601 cm⁻¹ absortion. Absorption intensities are recorded by the following abbreviations: s, strong; m, medium; w, weak. Proton NMR spectra were obtained on a Bruker (200 MHz) spectrometer by use of CDCl₃, CH₃OD, and d6-DMSO as solvent. Carbon-13 NMR spectra were obtained on a Bruker (50 MHz) spectrometer by used of CDCl₃, CH₃OD, and d6-DMSO as solvent. Carbon-13 chemical shifts are referenced to the center of the CDCl₃ triplet (δ 77.0 ppm). Multiplicities are recorded by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J, coupling constant (Hz). Elemental analyses were carried out on a Heraeus CHN-O RAPID element analyzer.

Standard procedure for bromination to prepare 5-halopyrazoles (3–13). To a solution of pyrazolones 1 or 5-hydroxypyrazoles 2 (1.0 equiv) in acetonitrile (5 mL), POBr₃, POCl₃, or POBr₃ (4.0 equiv) was added. The reaction mixture was heated to reflux for 24–72 h, stirred at room temperature for \sim 1 h. After the reaction was completed, the reaction mixture was cooled to 0°C and slowly quenched with ice/water and extracted with a 5:1 mixture of hexane and EtOAc. The extract was dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (20% EtOAc in hexanes as eluant) to give 5-halopyrazoles 3–13.

5-Bromo-1-phenyl-3-propyl-1H-pyrazole (3). ¹H NMR (CDCl₃, 300 MHz) δ 0.96 (t, 3 H, J = 7.2 Hz, CH₃), 1.58–1.73 (m, 2 H, CH₂), 2.62 (t, 2 H, J = 7.4 Hz,

CH₂), 6.24 (s, 1 H, Py), 7.32–7.42 (m, 3 H, ArH), 7.48–7.53 (m, 2 H, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 13.94, 22.65, 30.57, 109.23, 112.40, 125.48, 128.03, 128.81, 139.09, 155.17; IR (diffuse reflectance) 3053 (m), 1593 (m), 1494 (s), 1453 (s), 1407 (m), 1358 (m), 1167 (m), 1064 (w), 1018 (w), 981 (m) cm⁻¹; MS (ESI) m/z: 267 (M⁺+ 3), 265 (M⁺ + H). HRMS (ESI) calcd for $C_{12}H_{14}^{81}BrN_2$ (M⁺ + 3) 267.0320, found 267.0318; calcd for $C_{12}H_{14}^{79}BrN_2$ (M⁺ + H) 265.0340, found 265.0339; Anal. calcd for $C_{12}H_{13}BrN_2$: C, 54.36; H, 4.94; N, 10.57. Found: C, 54.38; H, 4.92; N, 10.59.

5-Bromo-3-isopropyl-1-phenyl-1H-pyrazole (4). 1 H NMR (CDCl₃, 300 MHz) δ 1.29 (d, 6 H, 2 × CH₃), 2.98–3.02 (m, 1 H, CH), 6.29 (s, 1 H, Py), 7.34–7.46 (m, 3 H, ArH), 7.50–7.55 (m, 2 H, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 22.59, 28.26, 107.43, 112.30, 125.58, 128.05, 128.83, 139.15, 160.89; IR (diffuse reflectance) 3050 (m), 2963 (s), 2926 (s), 2870 (m), 2854 (m), 1598 (s), 1498 (s), 1458 (m), 1432 (m), 1399 (m), 1375 (m), 1297 (m), 1235 (w), 1088 (m), 988 (m), 976 (m), 909 (m) cm $^{-1}$; MS (ESI) m/z: 267 (M $^{+}$ + 3), 265 (M $^{+}$ + H). HRMS (ESI) calcd for $C_{12}H_{14}{}^{81}BrN_2$ (M $^{+}$ + 3) 267.0320, found 267.0321; calcd for $C_{12}H_{14}{}^{79}BrN_2$ (M $^{+}$ + H) 265.0340, found 265.0338; Anal. calcd for $C_{12}H_{13}BrN_2$: C, 54.36; H, 4.94; N, 10.57. Found: C, 54.33; H, 4.90; N, 10.54.

5-Bromo-1,3-diphenyl-1H-pyrazole (5). Yellow solid in 81% yield; mp 74–75°C; 1 H NMR (CDCl₃, 300 MHz) δ 6.78 (s, 1 H, Py), 7.37–7.62 (m, 8 H, ArH), 7.82 (d, 2 H, J=6.4 Hz, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 107.71, 113.64, 125.65, 125.72, 128.41, 128.46, 128.71, 128.94, 132.35, 139.06, 153.00; IR (diffuse reflectance) 3053 (m), 1593 (m), 1494 (s), 1453 (s), 1407 (w), 1358 (m), 1168 (m), 1064 (m), 1018 (m), 981 (m) cm⁻¹; MS (ESI) m/z: 301 (M⁺+ 3), 299 (M⁺ + H). HRMS (ESI) calcd for $C_{15}H_{12}^{81}BrN_2$ (M⁺ + 3) 301.0163, found 301.0164; calcd for $C_{15}H_{12}^{79}BrN_2$ (M⁺ + H) 299.0184, found 299.0186; Anal. calcd for $C_{15}H_{11}BrN_2$: C, 60.22; H, 3.71; N, 9.36. Found: C, 60.19; H, 3.74; N, 9.35.

5-Bromo-3-phenyl-1-o-tolyl-1H-pyrazole (6). 1 H NMR (CDCl₃, 300 MHz) δ 2.15 (s, 3 H, CH₃), 6.78 (s, 1 H, Py), 7.29–7.42 (m, 7 H, ArH), 7.82–7.86 (m, 2 H, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 17.47, 106.08, 115.35, 125.62, 126.57, 128.26, 128.34, 128.73, 129.85, 130.99, 132.53, 136.51, 138.13, 152.89; IR (diffuse reflectance) 3049 (m), 2924 (s), 2854 (m), 1497 (s), 1457 (m), 1357 (m), 980 (m) cm⁻¹; MS (ESI) m/z: 315 (M⁺+ 3), 313 (M⁺ + H). HRMS (ESI) calcd for $C_{16}H_{14}^{81}BrN_2$ (M⁺ + 3) 315.0320, found 315.0316; calcd for $C_{16}H_{14}^{79}BrN_2$ (M⁺ + H) 313.0340, found 313.0338; Anal. calcd for $C_{16}H_{13}BrN_2$: C, 61.36; H, 4.18; N, 8.94. Found: C, 61.40; H, 4.21; N, 8.92.

5-Bromo-1-(4-methoxyphenyl)-3-phenyl-1H-pyrazole (7). White solid in 81% yield; mp 80–81°C; ¹H NMR (CDCl₃, 300

MHz) δ 3.85 (s, 3 H, OCH₃), 6.76 (s, 1 H, Py), 6.98 (d, 2 H, J = 8.8 Hz, ArH), 7.33–7.43 (m, 3 H, ArH), 7.50 (d, 2 H, J = 8.8 Hz, ArH), 7.82 (d, 2 H, J = 7.4 Hz, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 55.54, 107.12, 114.05, 125.57, 127.20, 128.29, 128.66, 132.13, 132.41, 152.64, 159.59; IR (diffuse reflectance) 2926 (m), 2846 (m), 1606 (m), 1516 (s), 1455 (m), 1362 (m), 1300 (w), 1250 (s), 1175 (m), 1030 (m), 979 (m), 833 (m) cm⁻¹; MS (ESI) m/z: 331 (M⁺+ 3), 329 (M⁺ + H); HRMS (ESI) calcd for $C_{16}H_{14}^{81}BrN_2O$ (M⁺ + 3) 331.0269, found 331.0273; calcd for $C_{16}H_{14}^{9}BrN_2O$ (M⁺ + H) 329.0290, found 329.0291; Anal. calcd for $C_{16}H_{13}BrN_2O$: C, 58.38; H, 3.98; N, 8.51. Found: C, 58.40; H, 3.95; N, 8.54.

5-Bromo-1-(4-chlorophenyl)-3-phenyl-1H-pyrazole (8). White solid; mp 94–95°C; 1 H NMR (CDCl₃, 300 MHz) δ 6.79 (s, 1 H, Py), 7.34–7.49 (m, 5 H, ArH), 7.57 (d, 2 H, J = 8.7 Hz, ArH), 7.81 (d, 2 H, J = 6.9 Hz, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 108.02, 113.58, 125.59, 126.80, 128.53, 128.71, 129.10, 132.06, 134.24, 137.48, 153.25; IR (diffuse reflectance) 3136 (w), 3059 (w), 2922 (w), 1593 (m), 1526 (m), 1494 (s), 1454 (s), 1392 (w), 1360 (s), 1303 (w), 1237 (m), 1094 (m), 1075 (m), 1028 (m), 978 (m), 830 (m), 763 (m), 691 (m), 572 (m), 508 (w) cm⁻¹; Anal. calcd for C₁₅H₁₀ClBrN₂: C, 54.00; H, 3.02; N, 8.40; Cl, 10.63. Found: C, 53.90; H, 2.92; N, 8.38; Cl, 10.79.

5-Bromo-1-(4-bromophenyl)-3-phenyl-1H-pyrazole (9). Yellow solid in 75% yield; mp 97–98°C; 1 H NMR (CDCl₃, 300 MHz) δ 6.79 (s, 1 H, Py), 7.34–7.43 (m, 3 H, ArH), 7.51 (d, 2 H, J=8.7 Hz, ArH), 7.62 (d, 2 H, J=8.7 Hz, ArH), 7.80 (d, 2 H, J=7.3 Hz, ArH); 13 C NMR (CDCl₃, 75 MHz) δ 108.09, 113.51, 122.22, 125.59, 127.05, 128.54, 128.71, 132.04, 132.07, 137.98, 153.28; IR (diffuse reflectance) 3131 (w), 3059 (m), 2923 (w), 1892 (w), 1589 (m), 1525 (m), 1493 (s), 1455 (s), 1391 (m), 1360 (m), 1302 (m), 1239 (m), 1068 (s), 978 (s), 949 (m), 827 (m), 763 (m), 691 (m), 571 (m), 507 (m) cm⁻¹; MS (ESI) m/z: 381 (M⁺ + 5), 379 (M⁺ + 3), 377 (M⁺ + 1); Anal. calcd for C₁₅H₁₁Br₂N₂: C, 47.53; H, 2.92; N, 7.39. Found: C, 47.26; H, 3.22; N, 7.21.

5-Bromo-3-phenyl-1-(2,4,6-trichlorophenyl)-1H-pyrazole (10). White solid in 79% yield; mp 98–99°C; ¹H NMR (CDCl₃, 300 MHz) δ 6.83 (s, 1 H, Py), 7.35–7.44 (m, 3 H, ArH), 7.50 (s, 2 H, ArH), 7.81 (d, 2 H, J = 7.2 Hz, ArH); ¹³C NMR (CDCl₃, 75 MHz) δ 106.75, 116.15, 125.77, 128.65, 128.68, 128.72, 131.96, 133.50, 136.36, 136.80, 154.51; IR (diffuse reflectance) 3079 (m), 2924 (m), 1742 (m), 1555 (s), 1527 (m), 1496 (s), 1454 (s), 1385 (m), 1357 (m), 1067 (m), 977 (m), 857 (m), 824 (s) cm⁻¹; MS (ESI) m/z: 405 (M⁺ + 5), 403 (M⁺ + 3), 401 (M⁺ + H); Anal. Calcd for C₁₅H₈BrCl₃N₂; C: 44.76; H: 2.00; N: 6.96, Found: C: 44.79; H: 1.98; N: 6.98.

5-Bromo-3-phenyl-1-(2-quinolinyl)-1H-pyrazole (11). White solid in 74% yield; mp 121-122°C; ¹H NMR (CDCl₃, 300 MHz) δ 6.88 (s, 1 H, Py), 7.39–7.57 (m, 3 H, ArH), 7.60–7.73 (m, 1 H, ArH), 7.74–7.78 (m, 1 H, ArH), 7.86-7.89 (m, 3 H, ArH), 8.04 (d, 1 H, J = 8.8 Hz, ArH), 8.13 (d, 1 H, J = 8.5 Hz, ArH), 8.29–8.32 (m, 1 H, ArH); ¹³C NMR (CDCl₃, 75 MHz) δ 110.03, 113.17, 116.34, 125.82, 126.87, 127.32, 127.54, 128.69, 128.71, 129.07, 130.28, 132.05, 138.69, 146.18, 150.57, 153.59; IR (diffuse reflectance) 3049 (w), 2921 (m), 1620 (m), 1600 (s), 1503 (s), 1433 (s), 1360 (s), 1229 (w), 1018 (m), 999 (s), 826 (s) cm⁻¹; MS (ESI) m/z: 352 (M⁺ + 3), 350 $(M^+ + H)$; HRMS (ESI) calcd for $C_{18}H_{13}^{81}BrN_3$ (M + 3) 352.0272, found 352.0270; calcd for $C_{18}H_{13}^{79}BrN_3$ $(M^+ + H)$ 350.0293, found 350.0290; Anal. calcd for C₁₈H₁₂BrN₃: C, 61.73; H, 3.45; N, 12.00. Found: C, 61.69; H, 3.42; N, 11.98.

5-Bromo-3-phenyl-1-(2-pyridinyl)-1H-pyrazole (*12*). White solid in 82% yield; mp 55–56°C; 1 H NMR (CDCl₃, 300 MHz) δ 6.83 (s, 1 H, Py), 7.30–7.46 (m, 4 H, ArH), 7.78–7.96 (m, 4 H, ArH), 8.58 (d, 1 H, J = 4.9 Hz); 13 C NMR (CDCl₃, 75 MHz) δ 109.37, 112.87, 118.52, 122.87, 125.75, 128.61, 128.67, 132.02, 138.41, 148.15, 151.80, 153.45; IR (diffuse reflectance) 3062 (w), 1587 (m), 1469 (s), 1444 (s), 1360 (m), 1308 (w), 1236 (w), 1076 (w), 999 (w) cm⁻¹; MS (ESI) m/z: 302 (M⁺ + 3), 300 (M⁺ + H); HRMS (ESI) calcd for $C_{14}H_{11}^{81}BrN_3$ (M + 3) 302.0116, found 302.0115; calcd for $C_{14}H_{11}^{79}BrN_3$ (M⁺ + H) 300.0136, found 300.0134; Anal. calcd for $C_{14}H_{10}BrN_3$: C, 56.02; H, 3.36; N14.00. Found: C, 56.05; H, 3.39; N, 14.03.

5-Chloro-3-phenyl-1-(2-pyridinyl)-1H-pyrazole (13). White solid in 71% yield; mp 56–57°C; ^1H NMR (CDCl $_3$, 300 MHz) δ 6.81 (s, 1 H, Py), 7.30–7.46 (m, 4 H, ArH), 7.79–7.90 (m, 4 H, ArH), 8.58 (d, 1 H, J=4.1 Hz); ^{13}C NMR (CDCl $_3$, 50 MHz) δ 109.42, 112.90, 118.55, 122.90, 125.79, 128.70, 132.05, 138.46, 148.16, 151.81, 153.50; IR (diffuse reflectance) 3045 (w), 2924 (m), 2856 (m), 1587 (m), 1456 (s), 1365 (m), 1003 (m) cm $^{-1}$; MS (ESI) m/z: 258 (M $^+$ + 3), 256 (M $^+$ + H); HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{11}^{37}\text{ClN}_3$ (M + 3) 258.0612, found 258.0616; calcd for $\text{C}_{14}\text{H}_{11}^{35}\text{ClN}_3$ (M $^+$ + H) 256.0642, found 256.0641; Anal. calcd for $\text{C}_{14}\text{H}_{10}\text{ClN}_3$: C, 65.76; H, 3.94; N, 16.43. Found: C, 65.73; H, 3.92; N, 16.46.

Standard procedure for the palladium-catalyzed dehalogenation of 5-halopyrazoles (14–23). A solution of 5-halopyrazoles (1.0 mmol, 1.0 equiv) and $PdCl_2(PPh_3)_2$ catalyst (0.03 mmol, 0.03 equiv, 3% w/w) in toluene (20 mL) was added with *t*-BuOK (2.0 mmol, 2.0 equiv) and heated at reflux for 1–4 h with bubble H_2 (flow rate 10 mL min⁻¹). After the reaction was completed, the reaction mixture was filtrated through Celite and the Celite bed was washed with toluene (10 mL \times 2). The fitrate was washed with water (10 mL \times 2),

brine (10 mL \times 2), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (20% EtOAc in Hexanes as eluant) to give the corresponding dehalogenation products **14–23** in 83–98% yields.

3-Isopropyl-1-phenyl-1H-pyrazole (15). 1 H NMR (CDCl₃, 300 MHz) δ 1.32 (d, 6 H, J = 6.9 Hz, 2 × CH₃), 3.07–3.12 (m, 1 H, CH), 6.28 (d, 1 H, J = 2.4 Hz, Py), 7.21–7.24 (m, 1 H, ArH), 7.38–7.43 (m, 2 H, ArH), 7.65 (d, 2 H, J = 8.1 Hz, ArH), 7.80 (d, 1 H, J = 2.4 Hz, Py); 13 C NMR (CDCl₃, 75 MHz) δ 22.82, 28.00, 104.42, 118.88, 125.80, 127.04, 129.28, 140.32, 161.00; IR (diffuse reflectance) 3049 (w), 2963 (s), 2927 (m), 2870 (m), 1601 (s), 1531 (s), 1504 (s), 1462 (m), 1385 (m), 1302 (m), 1225 (w), 1088 (m), 1042 (s), 986 (m), 946 (s), 902 (m), 753 (s), 689 (m), 501 (w) cm⁻¹; MS (ESI) m/z: 187 (M⁺ + H); HRMS (ESI) calcd for $C_{12}H_{15}N_2$ (M⁺ + H) 187.1235, found 187.1236.

3-Phenyl-1-O-tolyl-IH-pyrazole (17). ¹H NMR (CDCl₃, 300 MHz) δ 2.33 (s, 3 H, CH₃), 6.76 (d, 1 H, J = 1.4 Hz, Py), 7.27–7.45 (m, 7 H, ArH), 7.63 (d, 1 H, J = 1.4 Hz, Py), 7.91 (d, 2 H, J = 7.5 Hz, ArH); ¹³C NMR (CDCl₃, 75 MHz) δ 18.20, 103.53, 125.74, 126.09, 126.60, 127.81, 128.38, 128.60, 131.35, 131.90, 133.25, 133.72, 139.98, 152.25; IR (diffuse reflectance) 3062 (m), 2925 (m), 2852 (m), 1604 (m), 1583 (m), 1529 (m), 1504 (s), 1454 (s), 1386 (m), 1359 (m), 1264 (m), 1099 (w), 1046 (m), 957 (m), 942 (m), 752 (s), 718 (m), 692 (s), 452 (w) cm⁻¹; MS (ESI) m/z: 235 (M⁺ + H); HRMS (ESI) calcd for C₁₆H₁₅N₂ (M⁺ + H) 235.1235, found 235.1234; Anal. calcd for C₁₆H₁₄N₂: C, 82.02; H, 6.02; N, 11.96. Found: C, 81.98; H, 6.04; N, 11.94.

1-(2,6-Dichlorophenyl)-3-phenyl-IH-pyrazole (20). Yellow solid; mp 109–110°C; ¹H NMR (CDCl₃, 300 MHz) δ 6.82 (d, 1 H, J = 2.2 Hz, Py), 7.32–7.48 (m, 6 H, ArH), 7.56 (d, 1 H, J = 2.2 Hz, Py), 7.86–7.92 (m, 2 H, ArH); ¹³C NMR (CDCl₃, 75 MHz) δ 104.07, 125.99, 128.06, 128.60, 128.70, 130.61, 132.88, 132.95, 134.72, 136.54, 153.15; IR (diffuse reflectance) 3060 (w), 2920 (m), 1567 (m), 1530 (m), 1503 (s), 1478 (m), 1439 (m), 1454 (m), 1358 (m), 1261 (m), 1199 (m), 1073 (m), 1036 (m), 955 (m), 941 (m), 794 (s), 750 (s), 693 (m), 636 (w) cm⁻¹; Anal. calcd for C₁₅H₁₀Cl₂N₂: C, 62.30; H, 3.49; N, 9.69. Found: C, 61.96; H, 3.22; N, 9.80.

3-Phenyl-1-(2-quinolinyl)-1H-pyrazole (22). White solid; mp 127–128°C; 1 H NMR (CDCl₃, 300 MHz) δ 6.86 (d, 1 H, J=2.5 Hz, Py), 7.33–7.54 (m, 4 H, ArH), 7.71–7.76 (m, 1 H, ArH), 7.84 (d, 1 H, J=8.1 Hz, ArH), 7.96–8.06 (m, 3 H, ArH), 8.07–8.37 (m, 2 H, ArH), 8.86 (d, 1 H, J=2.5 Hz, Py); 13 C NMR (CDCl₃, 75 MHz) δ 105.85, 112.45, 125.81, 125.96, 126.97, 127.67, 128.28, 128.35, 128.67, 130.26, 132.82, 138.98, 146.43, 150.16, 153.99; IR (diffuse reflectance) 2916 (s), 2848 (m), 1598 (m), 1442 (m), 1359 (m), 1045 (w), 831 (m),

783 (m), 764 (m), 752 (m), 691 (m) cm $^{-1}$; MS (ESI) 0702)74291d 225m/z: 272 (M $^+$ + H). HRMS (ESI) calcd for $C_{18}H_{14}N_3$ (M $^+$ + H) 272.1188, found 272.1186; Anal. calcd for $C_{18}H_{13}N_3$: C, 79.68; H, 4.83; N, 15.49. Found: C, 79.71; H, 4.86; N, 15.52.

3-Phenyl-1-(2-pyridinyl)-1H-pyrazole (23). Yellow solid; mp 70–71°C; ¹H NMR (CDCl₃, 300 MHz) δ 6.80 (d, 1 H, J = 2.5 Hz, Py), 7.13-7.17 (m, 1 H, ArH), 7.38-7.49(m, 3 H, ArH), 7.80 (td, 1 H, J = 7.7, 1.4 Hz, ArH), 7.97 (d, 2 H, J = 7.20 Hz, ArH), 8.12 (d, 1 H, J = 8.2Hz, ArH), 8.42 (d, 1 H, J = 4.2 Hz, ArH), 8.62 (d, 1 H, J = 2.5 Hz, Py; ¹³C NMR (CDCl₃, 75 MHz) δ 105.22, 112.36, 121.11, 125.86, 128.15, 128.19, 128.59, 132.87, 138.52, 147.86, 151.46, 153.63; IR (diffuse reflectance) 3132 (w), 3059 (m), 1593 (s), 1530 (m), 1503 (m), 1469 (m), 1454 (s), 1360 (m), 1322 (w), 1304 (w), 1265 (m), 1144 (w), 1067 (m), 992 (m), 955 (m), 761 (s), 722 (m), 692 (m), 620 (w), 408 (m) cm^{-1} ; MS (ESI) 0702)74291d 225m/z: 222 (M⁺ + H). HRMS (ESI) calcd for $C_{14}H_{12}N_3$ (M^+ + H) 222.1031, found 222.1030; Anal. calcd for $C_{14}H_{11}N_3$: C, 76.00; H, 5.01; N, 18.99. Found: C, 76.03; H, 4.98; N, 18.96.

Acknowledgment. The authors thank China Medical University (CMU99-S-18) and the National Science Council of Republic of China for financial support (NSC 99-2320-B-039-014-MY3).

REFERENCES AND NOTES

- [1] Behr, L. C.; Fusco, R.; Jarboe, C. H. In The Chemistry of Heterocyclic Compounds, Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings; Weossberger, A., Ed.; Interscinence Publishers: New York, 1967; p 1.
- [2] Wiley, R. H.; Wiley, P. Pyrazolones, Pyrazolidones and Dertives; John Wiley and Sons: New York, 1964; p 102.
- [3] Golden, J. E.; Sanders, S. D.; Muller, K. M.; Bürli, R. W. Tetrahedron Lett 2008, 49, 794.
- [4] Bürli, R. W.; Hu, H.; Zou, X.; Muller, K.; Golden, J.; Frohn, M.; Adlam, M.; Plant, M. H.; Wong, M.; McElvain, M.; Regal, K.; Viswanadhan, V. N.; Tagari, P.; Hungate, R. Bioorg Med Chem Lett 2006, 16, 3713.
- [5] Banner, B.; Lester, B.; Joser, A.; Fotouhi, N.; Gillespie, P.; Goodnow, R. A.; Hamilton, M. M.; Haynes, N.-E.; Kowalczyk, A.; Myers, M. P.; Pietranico-Cole, S. L.; Sctto, N. R.; Thakkar, K. C.; Tilley, J. W. U.S. Pat. Appl. 2.007,049,632, 2007.
- [6] Tripathy, R.; Ghose, A.; Singh, J.; Bacon, E. R.; Angeles, T. S.; Yang, S. X.; Albom, M. S.; Aimone, L. D.; Herman, J. L.; Mallamo, J. P. Bioorg Med Chem Lett 2007, 17, 1793.
- [7] Balestra, M.; Bunting, H.; Chen, D.; Egle, I.; Forst, J.; Frey, J.; Isaac, M.; Ma, F.; Nugiel, D.; Slassi, A.; Steelman, G.; Sun, G.-R.; Sundar, B.; Ukkiramapandian, R.; Urbanek, R. A.; Walsh, S. Patent Appl. WO 2006071730, 2006.
- [8] Pégurier, C.; Collart, P.; Danhaive, P.; Defays, S.; Gillard, M.; Gilson, F.; Kogej, T.; Pasau, P.; Houtvin, N. V.; Thuyne, M. V.; van Keulen, B. Bioorg Med Chem Lett 2007, 17, 4228.
- [9] Costa, D.; Marques, A. P.; Reis, R. L.; Lima, J. L. C.; Fernandes, E. Free Radi Biol Med 2006, 40, 632.
- [10] Ramesh Kakarla, G. L.; Gerritz, S. W. Tetrahedron Lett 2007, 48, 4595.

- [11] Haddad, N.; Salvango, A.; Busacca, C. Tetrahedron Lett 2004, 45, 5935.
- [12] Tanitam, A.; Oyamada, Y.; Ofugi, K.; Fujimoto, M.; Iwai, N.; Hiyama, Y.; Suzuki, K.; Ito, H.; Terauchi, H.; Kawasaki, M.; Nagai, K.; Wachi. M.; Yamagishi, J.-I. J Med Chem 2004, 47, 3603
- [13] Tsurumi, K.; Abe, A.; Fujimura, H.; Asai, H.; Nagasaka, M.; Mikaye, H. Folia Pharmacol Jpn 1976, 72, 41.
- [14] Souza, F. R.; Souza, V. T.; Ratzlaff, V.; Borges, L. P.; Oliverira, M. R.; Bonacorso, H. G.; Zanatta, N.; Martins, M. A. P.; Mello, C. F. Eur J Pharmacol 2002, 451, 141.
- [15] Al-Omran, F.; El-Khair, A. A. J Heterocycl Chem 2004, 41, 327.
- [16] Sechi, M.; Sannia, L.; Carta, F.; Palomba, M.; Dallochio, R.; Dessi, A.; Derudas, M.; Zawahir, Z.; Neamati, N. Antiviral Chem Chemother 2005, 16, 41.
- [17] Cottineau, B.; Toto, P.; Marot, C.; Pipaud, A.; Chenault, J. Bioorg Med Chem Lett 2002, 12, 2105.
- [18] Kakiuchi, Y.; Sasaki, N.; Satoh-Masuoka, M.; Murofushi, H.; Murakami-Murofushi, K. Biochem Biophys Res Commun 2004, 320, 1351.
- [19] Sarojbasinidas, A. N.; Mishra, C. R.; Mittra, A. S. J Indian Chem Soc 1977, LIV, 485.
- [20] Huang, Y.-Y.; Lin, H.-C.; Cheng, K.-M.; Su, W.-N.; Sung, K.-C.; Lin, T.-P.; Huang, J.-J.; Lin, S.-K.; Wong, F. F. Tetrahedron 2009, 65, 9592.
- [21] Fuminori, K.; Hirohiko, K. JP Patent Augest 10-45588, 1998.
 - [22] Hardy, C. R. Adv Heterocycl Chem 1984, 36, 343.
- [23] Lavecchia, G.; Berteina-Raboin, S.; Guillaumet, G. Tetrahedron Lett 2004, 45, 2389.
- [24] Lynch, B. M.; Khan, M. A.; Teo, H. C.; Pedrotti, F. Can J Chem 1988, 66, 420.
- [25] Elnagdi, M. H.; Al-Awadi, N.; Erian, A. W. In Comprehensive Heterocyclic Chemistry II; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Pergamon: Oxford, 1996; Vol. 4, p 431.
- [26] Desenko, S. M.; Komykhov, S. A.; Orlov, V. D.; Meier, H. J Heterocycl Chem 1988, 35, 989.
- [27] Quiroga, J.; Insusuashy, B.; Craz, S.; Hernandez, P.; Bolafios, A.; Moreno, R.; Homoza, A.; de Almedias, R. H. J Heterocycl Chem 1998, 35, 333.
- [28] Basaif, S. A.; Hassan, M. A.; Gobouri, A. A. Dyes Pigments 2007, 72, 387.
 - [29] Karci, F.; Ertan, N. Dyes Pigments 2002, 55, 99.
 - [30] Ho, Y. W. Dyes Pigments 2005, 64, 223.
- [31] Marchetti, F.; Pettinari, C.; Pettinari, R. Coord Chem Rev 2005, 249, 2909.
- [32] Debarge, S.; Violeau, B.; Bendaoud, N.; Jouannetaud, M.-P.; Jacquesy, J.-C. Tetrahedron Lett 2003, 44, 1747.
 - [33] Effenberger, F. Angew Chem Int Ed 2002, 114, 1775.
- [34] Poschalko, A.; Welzig, S.; Treu, M.; Nerdinger, S.; Mereiter, K.; Jordis, U. Tetrahedron 2002, 58, 1513.
 - [35] Choi, H. Y.; Chi, D. Y. J Am Chem Soc 2001, 123, 9202.
- [36] Küenburg, B.; Czollner, L.; Fröhlich, J.; Jordis, U. Org Process Res Dev 1999, 3, 425.
 - [37] Zask, A.; Helquist, P. J Org Chem 1978, 43, 1619.
- [38] Vincent, T.; Spinelli, S.; Guibal, E. Ind Eng Chem Res 2003, 42, 5968.
- [39] Sajiki, H.; Kume, A.; Hattori, K.; Nagase, H.; Hirota, K. Tetrahedron Lett 2002, 43, 7251.
- [40] Mitoma, Y.; Nagashima, S.; Simion, C.; Simon, A. M.; Yamada, T.; Mimura, K.; Ishimoto, K.; Tashiro, M. Environ Sci Technol 2001, 35, 4145.
- [41] Morra, M. J.; Borek, V.; Koolpe, J. J Environ Qual 2000, 29, 706.

- [42] Grushin, V. V.; Alper, H. Chem Rev 1994, 94, 1047.
- [43] Hudlicky, M. In Comprehensive Organic Synthesis; Trost, B. M. Fleming, I. Eds.; Pergamon: Oxford, 1991; Vol. 8, p 895.
 - [44] Hites, R. A. Acc Chem Res 1990, 23, 194.
 - [45] Pinder, A. R. Synthesis 1980, 425.
- [46] Alonso, F.; Beletskaya, I. P.; Yus, M. Chem Rev 2002, 102, 4009.
- [47] Navarro, O.; Marion, N.; Oonishi, Y.; Kelly, R. A., III; Nolan, S. P. J Org Chem 2006, 71, 685.
- [48] Arcadi, A.; Cerichelli, G.; Chiarini, M.; Vico, R.; Zorzan, D. Eur J Org Chem 2004, 16, 3404.
- [49] Hara, T.; Mori, K.; Oshiba, M.; Mizugaki, T.; Ebitani, K.; Kaneda, K. Green Chem 2004, 6, 507.
- [50] Navarro, O.; Kaur, H.; Mahjoor, P.; Nolan, S. P. J Org Chem 2004, 69, 3173.
- [51] Chen, J.; Zhang, Y.; Yang, L.; Zhang, X.; Liu, J.; Li, L.; Zhang, H. Tetrahedron 2007, 63, 4266.
- [52] Calò, V.; Nacci, A.; Monopoli, A.; Damascelli, A.; Ieva E.; Cioffi, N. J Organomet Chem 2007, 692, 4397.
- [53] Fujita, K.; Owaki, M.; Yamaguchi, R. Chem Commun 2002, 24, 2964.
 - [54] Guo, H.; Kanno, K.-I.; Takahashi, T. Chem Lett 2004, 33, 1356.
- [55] Kuhl, S.; Schneider, R.; Fort, Y. Adv Synth Catal 2003, 345, 341.
- [56] Desmarets, C.; Kuhl, S.; Schneider, R.; Fort, Y. Organometallics 2002, 21, 1554.
 - [57] Terstiege, I.; Maleczka, R. E., Jr. J Org Chem 1999, 64, 342.
- [58] Parry, R. J.; Li, Y.; Gomez, E. E. J Am Chem Soc 1992, 114, 5946.
- [59] Dorman, G.; Otszewski, J. D.; Prestwich, G. D. J Org Chem 1995, 60, 22927.
- [60] Handy, S. T.; Bregman, H.; Lewis, J.; Zhang, X.; Zhang, Y. Tetrahedron Lett 2003, 44, 427.
 - [61] Huppatz, J. L. Aust J Chem 1983, 36, 135.
- [62] Nazarinia, M.; Sharifian, A.; Shafiee, A. J Heterocycl Chem 1995, 32, 223.
- [63] Wang, X.-J.; Tan, J.; Grozinger, K. Tetrahedron Lett 2000, 41, 4713.
- [64] Djuric, S. W.; BaWaung, N. Y.; Basha, A.; Liu, H.; Luly, J. R.; Madar, D. J.; Sciotti, R. J.; Tu, N. P.; Wagenaar, F. L.; Wiedeman, P. E.; Zhou, X.; Ballaron, S.; Bauch, J.; Chen, Y.-W.; Chiou, X. G.; Fey, T.; Gauvin, D.; Gubbins, E.; Hsieh, G. C.; March, K. C.; Mollison, K. W.; Pong, M.; Shaughnessy, T. K.; Sheets, M. P.; Smith, M.; Trevillyan, J. M.; Warrior, U.; Wegner, C. D.; Carter, G. W. J. Med Chem. 2000, 43, 2975.
- [65] Zhang, J.; Didierlaurent, S.; Fortin, M.; Lefrançois, D.; Uridat, E.; Vevert, J. P. Bioorg Med Chem Lett 2000, 10, 2575.
- [66] Wang, X.-J.; Tan, J.; Grozinger, K. Tetrahedron Lett 2000, 41, 4713.
- [67] Heck, R. F. Palladium Reagents in Organic Synthesis; Academic Press: New York, 1978.
 - [68] Winter, M. Helv Chim Acta 1963, 46, 1754.
- [69] Carrillo, J. R.; Cossío, F. P.; Díaz-Ortíz, A.; Gómez-Escalonilla, M. J.; Lecea, A. D. L. B.; Moreno, A.; Prieto, P. Tetrahedron 2001, 57, 4179.
- [70] Alper, H.; Prickett, J. E.; Wollowitz, S. J Am Chem Soc 1977, 99, 4330.
- [71] Singh, O. V.; Huang, W.-J.; Chen, C.-H.; Lee, S.-S. Tetrahedron Lett 2007, 48, 8166.
- [72] Viciu, M. S.; Grasa, G. A.; Nolan, S. P. Organometallics 2001, 20, 3607.
- [73] Ofele, K.; Herrmann, W. A.; Mihailos, D.; Elison, M.; Herdtweck, E.; Scherer, W.; Mink, J. J Organomet Chem 1993, 459, 177.